now the phama just a biccycle walk to slow, next time will upgrade to the motor....haha.still can easy chase the bicycle,when one day be a ferrari,i dont no how le...good luck.
Mr.President D.Trump will lose the election in this November 2020 or not ? If yes how about Dow index will plunge or up ? Please experts here who could explain ? If Trump lose how about KLCI and pharmaceutical and glove conuters ? Could further uptrend ? or Plunge ... ? Para hadirin dan tuan tuan dan puan puan, keputusan piliharaya utk Amerika Syarikat pada bulan 11 ni jika En. D.Trump terkandas apa akan jadi pada KLCI, harga saham pharmaceutical dan sarung tangan di Malaysia ? siapa pakar di sini boleh tolong lah explain. Tks
The double conflicting statements by Khairy is disturbing. The first statement says Pharmaniaga is the govt. choice for the vaccine. The second says other medical companies can be considered. Now which is which.
Masila The double conflicting statements by Khairy is disturbing. The first statement says Pharmaniaga is the govt. choice for the vaccine. The second says other medical companies can be considered. Now which is which. 30/07/2020 9:48 PM
Second statement was asked in parliament. Of course he has to give non bias answer regarding tender offering. After all, there are probably less than 10 companies that able to do the task. So you need to study more which company has the best prospect and capacity in securing this 'bottling' thing.
How else to buy cheap while keeping away others disinterested. We see this kind of attitude from many in this forum too and not just at this stock. They will sing many different tunes to make you sell while they quietly collect. Even Sharks resorts to such manipulation.
6 companies in Phase III now 1) Moderna (USA) 2) BioNTech, Pfizer & Fosun Pharma (Germany, USA & China) 3) AstraZeneca & University of Oxford (UK & Sweden) 4) Sinopharm (China) 5) Sinovac Biotech (China) 6) Murdoch Children’s Research Institute (Australia)
I will not deny that the upcoming performance for Pharmaniaga will become a safe heaven since MCO lockdown moment strong demand to their products, just depends to it's share price, if comes lower can consider simpan
Reuters: According to a Reuters report, sources from the US security services say a company targeted by two Chinese hackers indicted in the US earlier this month is Moderna, a leading coronavirus vaccine developer. How do you comment on this?
Wang Wenbin: Recently so-called sources from the US government have been accusing China of hacking to steal technology and data of US vaccine research, but there has been no evidence whatsoever. Such allegations are pure slander. The sources are all cited anonymously. The international community can see through such vilifying ploys.
As we've repeatedly said, China is leading the world in COVID-19 vaccine research and development. We don't need to get ahead by theft and we have never done that. On the contrary, we are worried about a certain thieving country stealing our technology by hacking.
We urge certain US government departments and individuals to stop smearing China with rumors. We also call on relevant media to deny such anonymous groundless disinformation platforms and channels for dissemination.
Talk with the facts and figures for Pharma, the last quarter earning was superb at 8.57 sen as higher demands of it medicines/medical products from Malaysia & Indonesia BOOST up it earning. It for sure is one of the beneficiary of Covid-19 beside glove sector. When Vaccine of Covid-19 to be ready, may be just few months time before Trump election in Nov, this will be added advantages for it future earning!
With Q1 2020 of Earning @ 8.57 sen, annualized simply to be 34 sen. With PE of 20, it worth RM6.80. With PE of 30, it worth RM10.20!
So, share price of this counter is just recovering from it losses from previous sell off due to Q4 2019 bad quarter result. The reason of Q4 2019 bad results was due to full recognition on the remaining unamortised Pharmacy Information System (PhIS) costs. This represents a one-off non-cash item and will be better for the Group’s profitability moving forward as it will no longer need to bear this cost in the future!
Thus, Pharma currently just starts to go back to it previous glory. With it current supply of medicines and medical related products (including face mask..etc) to all the government clinics and hospitals in Malaysia and Indonesia (of course some private hospitals as well), this is enough to boost up it earning. The latest excellent earning results @ Q1 2020 has proven this!
Certainly, Covid-19 vaccine out will be added advantages for it future earning as it will be one of the government trusted pharmaceutical manufacturing facilities to handle the vaccine when available.
Link for latest News from Malay Mail: Pharmaniaga to grow manufacturing business, expand to Indonesia
A very good reference for you all regarding history of H1N1 in 2009. Vaccine of H1N1 is available surprisingly in just around 8 months of time from US. Read the history as per below link which is from US CDC (Center of Disease Control):
APPROVAL: Regulators in each country review the trial results and decide whether to approve the vaccine or not. During a pandemic, a vaccine may receive emergency use authorization before getting formal approval.
Coronavirus Vaccine Trials Advance in Race for Covid-19 Protection
Moderna, AstraZeneca and China's CanSino are among the leading candidates to produce a shot to fight the pandemic.
Updated: July 31, 2020, 9:45 PM
The global push to develop and secure coronavirus vaccines is accelerating, with researchers reporting positive developments in early studies and countries signing deals to lock up supplies.
More than 160 vaccines are under development globally, spurred by the U.S. government's Operation Warp Speed program and other fast-track initiatives. Shots from the University of Oxford with AstraZeneca Plc, Moderna Inc. and a partnership of Pfizer Inc. and BioNTech SE are among the vanguard. China's CanSino Biologics has received authorization for a limited deployment of its shot among the Chinese military, and the Russian Defense Ministry has suggested its state-backed vaccine candidate could soon be ready for use.
Progress on treating those already infected has been slower, with Gilead Sciences Inc.'s remdesivir receiving an emergency use authorization in the U.S. and decades-old generic drug dexamethasone showing promise in studies. Here's the current state of play on vaccines and treatments.
Worldwide supply may not reach 1 billion doses until the first quarter of 2022, Airfinity forecasts.
Investing in production capacity all over the world is seen as one of the keys to solving the dilemma, and pharma companies are starting to outline plans to deploy shots widely. Sanofi and Glaxo intend to provide a significant portion of worldwide capacity in 2021 and 2022 to a global initiative that’s focused on accelerating development and production and distributing shots equitably.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Fluxus
18 posts
Posted by Fluxus > 2020-07-30 09:33 | Report Abuse
Steady!